mbrubeckMay 23
@tapirgirl @nev This is not a docket to comment on vaccine availability rules. This is for comments on yesterday's meeting of the advisory board that decides which COVID variant this year's boosters should target. More details about that meeting here: https://arstechnica.com/health/2025/05/fda-advisors-for-covid-shots-left-in-the-dark-over-how-theyll-be-regulated/
Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot

FDA advisors wanted to know what switching strains means. FDA couldn’t answer.

Ars Technica
Show threadTapir Girl
@mbrubeck Thanks for the clarification. Given that the two issues seem to be intertwined, do you think there is a downside to commenting on the availability issue through that form?
May 24 at 12:16amWeb
Show threadmbrubeckMay 24
@tapirgirl Probably no downside, but it's going to a group that apparently has no input into the decision. :(